Pfizer launches the first vaccine against 20 serotypes of the viruses that cause pneumonia

The first 20-valent pneumococcal conjugate vaccine (PCV20) is now available in Spain for the prevention of invasive pneumococcal disease and pneumococcal pneumonia, caused by 20 serotypes of the bacterium Streptococcus pneumoniae, in adults over 18 years of age. It’s called APEXXNAR® and it’s from Pfizer, and it promises protect against the largest number of serotypes that are currently responsible for 70% of pneumococcal pneumonia requiring hospitalization in adults in Spain.

Therefore, it includes capsular polysaccharide conjugates for the 13 serotypes already included in ‘PREVENAR 13’ (its previous version), it also contains capsular polysaccharide conjugates for seven additional serotypes that cause invasive pneumococcal disease (IPD) and have been associated with high case fatality rates, antibiotic resistance and/or meningitis.

PCV20 is expected to induce immunological memory and help provide protection against pneumococcal disease, including nonbacteremic pneumonia, particularly in older adults. “In principle it is only one dose, and only with time will we know if it will be the only one that has to be administered”, said the coordinator of the Pneumoexperts in Prevention Group, Federico Martinon.

The Article Is In Spanish🡽

Scroll to Top